Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The impact of genetic polymorphisms on the pharmacokinetics of efavirenz in African children.

British journal of clinical pharmacology - 1 Jul 2016

Bienczak Andrzej, Cook Adrian, Wiesner Lubbe, Olagunju Adeniyi, Mulenga Veronica, Kityo Cissy, Kekitiinwa Addy, Owen Andrew, Walker A Sarah, Gibb Diana M, McIlleron Helen, Burger David, Denti Paolo

Abstract excerpt

AIMS: Using a model-based approach, the efavirenz steady-state pharmacokinetics in African children is characterized, quantifying demographic and genotypic effects on the drug's disposition. Simulations are also conducted allowing prediction of optimized doses of efavirenz in this population. METHODS: We modelled the steady-state population pharmacokinetics of efavirenz in Ugandan and Zambian children using...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alkynes
Share to Benzoxazines

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cyclopropanes

Share to Cytochrome P-450 CYP2B6

Share to Nonlinear Dynamics

Share to Reverse Transcriptase Inhibitors

Share to Uganda

Share to Zambia

Source

Open in PubMed Open full text

Identifiers

PMID: 26991336
DOI: 10.1111/bcp.12934
PMCID: PMC4917805

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The impact of genetic polymorphisms on the pharmacokinetics of efavirenz in African children.PMID 26991336Read ↗

Pharmacogenetics of plasma efavirenz exposure in HIV-infected adults and children in South Africa.Semantic proximity Read ↗

Genetic and non-genetic factors influencing efavirenz population pharmacokinetics among human immunodeficiency virus-1-infected children in Ethiopia.Semantic proximity Read ↗

CYP2B6 Haplotype Predicts Efavirenz Plasma Concentration in Black South African HIV-1-Infected Children: A Longitudinal Pediatric Pharmacogenomic Study.Semantic proximity Read ↗

Pharmacogenetic-based efavirenz dose modification: suggestions for an African population and the different CYP2B6 genotypes.Semantic proximity Read ↗

A pharmacokinetic and pharmacogenetic study of efavirenz in children: dosing guidelines can result in subtherapeutic concentrations.Semantic proximity Read ↗

A novel polymorphism in ABCB1 gene, CYP2B6*6 and sex predict single‐dose efavirenz population pharmacokinetics in UgandansSemantic proximity Read ↗

Sub‐ and supratherapeutic efavirenz plasma concentrations with risk for HIV therapy failure are mainly genetically explained in Ugandan children: The prospective GENEFA cohort studySemantic proximity Read ↗

Influence of the cytochrome P450 2B6 genotype on population pharmacokinetics of efavirenz in human immunodeficiency virus patients.Semantic proximity Read ↗

Pharmacogenetics of Dolutegravir Plasma Exposure Among Southern Africans With Human Immunodeficiency VirusSemantic proximity Read ↗

Physiologically Based Pharmacokinetic Modeling to Determine the Impact of CYP2B6 Genotype on Efavirenz Exposure in Children, Mothers and Breastfeeding Infants.Semantic proximity Read ↗

Pharmacometric Characterization of Efavirenz Developmental Pharmacokinetics and Pharmacogenetics in HIV-Infected ChildrenSemantic proximity Read ↗

Population Pharmacokinetics Analysis To Inform Efavirenz Dosing Recommendations in Pediatric HIV Patients Aged 3 Months to 3 Years.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.